BYETTA PEN Injection 250MCG/ML 1.2ML

Here are some key clinical differences between tirzepatide (Mounjaro) and exenatide (Byetta):

– Mechanism of action: Tirzepatide is a dual GIP and GLP-1 receptor agonist, while exenatide is a GLP-1 receptor agonist only. Tirzepatide activates both incretin hormone pathways, which is thought to lead to greater efficacy.

– Efficacy for HbA1c reduction: In clinical trials, tirzepatide reduced HbA1c by up to 2.37% compared to placebo after 52 weeks. Exenatide reduced HbA1c by around 1% compared to placebo in trials. So tirzepatide appears more potent for lowering blood sugar.

– Weight loss effects: Tirzepatide has shown superior weight loss compared to exenatide in head-to-head clinical trials. After 72 weeks, tirzepatide led to an average of 25.6 lbs weight loss versus 9.0 lbs with exenatide.

– Dosing frequency: Tirzepatide is a once weekly injection, whereas exenatide is taken twice per day. The less frequent dosing may improve adherence.

– Side effects: Both GLP-1 drugs can cause GI side effects like nausea and vomiting, but tirzepatide has a higher incidence. Exenatide may cause more injection site reactions.

– Cost/availability: Exenatide is available as a generic, making it less expensive. Tirzepatide was only recently approved in 2022 so is still brand-name only.

In summary, tirzepatide appears to offer greater glucose-lowering and weight loss effects but with increased side effects and cost compared to the older GLP-1 drug exenatide. The once-weekly dosing of tirzepatide is also an advantage.